Full-Time

Key Account Manager-Dry Eye-Fresno

Harrow

Harrow

201-500 employees

Compounds ophthalmic formulations; markets branded drugs

Compensation Overview

$120k/yr

+ Bonus

Fresno, CA, USA

In Person

On-site in Fresno, California; ~70-75% travel with overnight stays.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Harrow

See people who can refer or advise you

Requirements
  • Bachelor’s degree in a related field
  • Has 1-4 years of pharmaceutical or medical device sales experience
  • Ophthalmic experience is beneficial (desirable)
  • Knowledge of payer landscape, Commercial, Medicare Part D, and dual eligibility
  • Knowledge of how physicians make decisions regarding patient care for various therapies
  • Excellent presentation and interpersonal skills
  • Superior communication and written skills
  • Ability to build, develop, and foster longstanding relationships with customers
  • Ability to quickly absorb product and practice information and offer solutions that resonate
  • Experience with the execution of strategic and targeted business plans around priorities and goals
  • Proficient with MS Office products, including Word, Excel, and PowerPoint
  • Clinical understanding in the specialty of ophthalmology (desirable)
  • Ability to multitask, adjusting priorities as needed
  • Good problem-solving and analytical skills
  • Ability to become proficient with the CRM System
  • 70% weekly travel in a defined territory with overnights required
  • Understanding of the Pharmaceutical Industry’s Code of Practice
  • Comply with all state and federal-specific legislation and regulatory requirements
  • Manage expenses in a thoughtful, responsible, and ethical manner
Responsibilities
  • Meet or exceed quarterly sales revenue and product goals
  • Takes 100% ownership and accountability to reach the goals set by the company
  • Focus is on the development of new customers while converting the existing customer base
  • Entrepreneurial mindset to analyze, develop, and grow the territory business
  • Drive demand through organic pull-through and deploy any and all reimbursement solutions
  • Call on ophthalmic healthcare professionals in defined markets
  • Develop critical physician and staff relationships within the assigned geography
  • Utilizes internal resources when developing quarterly action plans and partnering with accounts
  • All sales activity is adequately recorded in CRM in a timely manner
  • Competent in PowerPoint, Excel, Word & Outlook
  • Maintain an in-depth and professional level understanding of our ophthalmic product portfolio and the competition
  • Articulate the clinical benefits of the products/formulations and our solutions that complement them in a compliant manner
  • Act with a sense of urgency at all levels of customer care and follow up
  • Collaborate with internal departments and peers
  • Ability to travel throughout the assigned geography on a routine basis
  • Expected travel in the field will be about 75-80%, which may include overnight stays
  • Understand the Pharmaceutical Industry’s Code of Practice
  • Comply with all state and federal-specific legislation and regulatory requirements
  • Manage expenses in a thoughtful, responsible, and ethical manner
  • Resourceful thinker that may not have a complete roadmap to success but finds the resources available to win and prosper
  • Acts as the liaison for customers with continual follow-up
  • Submits all required reports, including monthly expense reports, on time
Desired Qualifications
  • Ophthalmic experience is beneficial
  • Clinical understanding in the specialty of ophthalmology is preferred

Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.

Company Size

201-500

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1998

Get referred to Harrow

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Harrow reported Q2 2026 revenue of $70.7 million, up 11% year over year.
  • VEVYE pricing fixes, IHEEZO’s July 1 2026 increase, and BYOOVIZ launched in July.
  • TYRVAYA acquisition adds over $30 million expected 2027 revenue and expands dry-eye depth.

What critics are saying

  • Q2 2026 adjusted EBITDA was negative $1.2 million, exposing fragile profitability.
  • Compounded revenue should fall 10% to 20% in 2026, pressuring Harrow’s legacy engine.
  • OSRX and Bausch litigation still hangs over ImprimisRx, risking injunctions, damages, and distraction.

What makes Harrow unique

  • Harrow sells exclusively ophthalmology products through compounding, branded drugs, and biosimilars.
  • Its 50-state direct commercial platform reaches ophthalmologists, hospitals, and ambulatory surgery centers.
  • Mark Baum’s acquisition playbook keeps adding late-stage eye assets like TYRVAYA and BYOOVIZ.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

25%

1 year growth

25%

2 year growth

25%
Yahoo Finance
Aug 11th, 2026
Harrow reiterates $350M–$365M revenue guidance, plans $30M TYRVAYA acquisition

Harrow reported second-quarter revenue of $70.7 million, up 11% year-over-year, driven by stronger demand for VEVYE, IHEEZO and specialty products. The ophthalmic pharmaceutical company reiterated full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million. VEVYE generated $29.4 million in quarterly revenue, up nearly 58% year-over-year, whilst IHEEZO contributed $15.6 million. Management expects second-half growth from improved VEVYE pricing, IHEEZO's 25% net price increase, and the BYOOVIZ and VERKAZIA launches. Harrow plans to acquire global rights to TYRVAYA for $30 million in cash, expecting more than $30 million of revenue in 2027 if the deal closes. The company also advanced pipeline programmes G-MELT and YOCHIL, targeting FDA submissions in 2027.

Associated Press
Jul 1st, 2026
Harrow launches BYOOVIZ biosimilar in $9B US anti-VEGF market under Samsung Bioepis deal

Harrow has announced the commercial launch of BYOOVIZ (ranibizumab-nuna) in the United States, an FDA-approved biosimilar referencing LUCENTIS. The launch follows Harrow's exclusive US commercialisation agreement with Samsung Bioepis, which also includes rights to OPUVIZ (aflibercept-yszy), another ophthalmology biosimilar. BYOOVIZ is approved for treating Neovascular Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization. It was designated by the FDA as the first interchangeable ophthalmology biosimilar in the US. The product joins Harrow's expanding retina franchise, which includes IHEEZO and TRIESENCE. The company aims to strengthen its position in the estimated $9 billion US anti-VEGF market, providing retina specialists with buy-and-bill products for treating sight-threatening retinal diseases.

Yahoo Finance
Jun 10th, 2026
Harrow re-launches VERKAZIA to treat vernal keratoconjunctivitis in children

Harrow has re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy for vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. The re-launch includes a comprehensive commercial strategy focused on physician education, patient access and affordability initiatives. VERKAZIA is a calcineurin inhibitor immunomodulator that targets VKC's underlying inflammatory mechanisms and may reduce the need for steroid rescue, which carries risks including glaucoma or cataract formation. VKC can lead to sight-threatening conditions if left untreated. Chief Executive Officer Mark Baum said the re-launch aims to ensure dependable supply and remove access barriers for this evidence-based, steroid-sparing treatment. VERKAZIA represents the second of three priority products in Harrow's portfolio currently being executed.

Yahoo Finance
May 20th, 2026
B.Riley cuts Harrow price target to $60 amid pricing pressure but maintains buy rating

Harrow, Inc. (NASDAQ:HROW) had its price target reduced to $60 from $65 by B.Riley on 14 May, though the firm maintained its Buy rating. The adjustment followed first-quarter results impacted by weaker pricing for VEVYE and lowered near-term growth expectations. The Nashville-based ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million, including an $8 million non-recurring adjustment related to VEVYE commercial coverage. Despite pricing pressures, the company highlighted record VEVYE prescriptions and strong performance from IHEEZO and TRIESENCE, with unit demand rising 18% and doubling respectively year over year. Harrow reaffirmed full-year revenue guidance of $350–$365 million. B.Riley cited upcoming product launches, reimbursement coding catalysts and expanding commercial leverage as factors supporting stronger second-half performance.

Yahoo Finance
May 12th, 2026
Harrow reports $44.2M Q1 revenue amid $8M gross-to-net modelling hit, reaffirms $350M–365M 2026 guidance

Harrow Inc reported Q1 2026 revenue of $44.2 million and negative adjusted EBITDA of $12.7 million, whilst reaffirming full-year revenue guidance of $350 million to $365 million. The company expects Q2 revenue between $71 million and $81 million. VEVYE generated $20.9 million in revenue, with new prescriptions growing approximately 25% sequentially and market share reaching 14%. The company doubled its sales force by hiring over 90 professionals. TRIESENCE unit volume surged 136% year-over-year. However, the company faced an $8 million revenue reduction due to VEVYE coverage modelling issues. IHEEZO contributed just $1.9 million as channel inventory absorbed demand. High-deductible patient challenges also impacted net pricing, requiring business rule adjustments in mid-April.